Kawai Kenji, Sato Yu, Kawakami Rika, Sakamoto Atsushi, Cornelissen Anne, Mori Masayuki, Ghosh Saikat, Kutys Robert, Virmani Renu, Finn Aloke V
CVPath Institute, Gaithersburg, MD, USA.
University of Maryland, School of Medicine, Baltimore, MD, USA.
J Multidiscip Healthc. 2022 Jun 1;15:1261-1276. doi: 10.2147/JMDH.S251861. eCollection 2022.
It is very unusual to see evidence of arterial calcification in infants and children, and when detected, genetic disorders of calcium metabolism should be suspected. Generalized arterial calcification of infancy (GACI) is a hereditary disease, which is characterized by severe arterial calcification of medium sized arteries, mostly involving the media with marked intimal proliferation and ectopic mineralization of the extravascular tissues. It is caused by inactivating variants in genes encoding either ENPP1, in a majority of cases (70-75%), or ABCC6, in a minority (9-10%). Despite similar histologic appearances between ENPP1 and ABCC6 deficiencies, including arterial calcification, organ calcification, and cardiovascular calcification, mortality is higher in subjects carrying the ENPP1 versus ABCC6 variants (40% vs 10%, respectively). Overall mortality in individuals with GACI is high (55%) before the age of 6 months, with 24.4% dying in utero or being stillborn. Rare cases show spontaneous regression with age, while others who survive into adulthood often manifest musculoskeletal complications (osteoarthritis and interosseous membrane ossification), enthesis mineralization, and cervical spine fusion. Despite recent advances in the understanding of the genetic mechanisms underlying this disease, there is still no ideal therapy for the resolution of vascular calcification in GACI. Although bisphosphonates with anti-calcification properties have been commonly used for the treatment of CAGI, their benefit is controversial, with favorable results reported at one year and questionable benefit with delayed initiation of treatment. Enzyme replacement therapy with administration of recombinant form of ENPP1 prevents calcification and mortality, improves hypertension and cardiac function, and prevents intimal proliferation and osteomalacia in mouse models of ENPP1 deficiency. Therefore, newer treatments targeting genes are on the horizon. In this article, we review up to date knowledge of the understanding of GACI, its clinical, pathologic, and etiologic understanding and treatment in support of more comprehensive care of GACI patients.
在婴儿和儿童中发现动脉钙化的证据非常罕见,一旦检测到,应怀疑钙代谢的遗传紊乱。婴儿期全身性动脉钙化(GACI)是一种遗传性疾病,其特征是中等大小动脉严重钙化,主要累及中膜,伴有明显的内膜增生和血管外组织的异位矿化。它是由编码ENPP1的基因(大多数病例,70 - 75%)或ABCC6的基因(少数病例,9 - 10%)的失活变体引起的。尽管ENPP1和ABCC6缺乏症在组织学表现上相似,包括动脉钙化、器官钙化和心血管钙化,但携带ENPP1变体的受试者的死亡率高于携带ABCC6变体的受试者(分别为40%和10%)。GACI患者在6个月前的总体死亡率很高(55%),其中24.4%在子宫内死亡或死产。罕见病例显示随着年龄增长会自发消退,而其他存活至成年的患者通常表现出肌肉骨骼并发症(骨关节炎和骨间膜骨化)、附着点矿化和颈椎融合。尽管最近在理解这种疾病的遗传机制方面取得了进展,但对于GACI中血管钙化的解决仍没有理想的治疗方法。尽管具有抗钙化特性的双膦酸盐已普遍用于治疗CAGI,但其益处存在争议,一年时报告有良好效果,但治疗开始延迟时益处存疑。在ENPP1缺乏的小鼠模型中,给予重组形式的ENPP1进行酶替代疗法可预防钙化和死亡,改善高血压和心脏功能,并预防内膜增生和骨软化。因此,针对基因的新疗法即将出现。在本文中,我们回顾了关于GACI的最新认识,包括其临床、病理、病因学方面的认识以及治疗方法,以支持对GACI患者进行更全面的护理。